SCHEDULE: Biotechnology Value Fund Discloses NewcelX Stake
Beneficial Ownership Disclosure
Biotechnology Value Fund and its affiliates reported a beneficial ownership of 0.6% in NewcelX Ltd. common shares.
Summary
- Biotechnology Value Fund, L.P. and its affiliated entities, including BVF I GP LLC, Biotechnology Value Fund II, L.P., BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP Holdings LLC, BVF Partners L.P., BVF Inc., and Mark N. Lampert, collectively reported beneficial ownership in NewcelX Ltd.
- As of November 4, 2025, the Reporting Persons and a Partners managed account beneficially owned an aggregate of 28,732 Common Shares of NewcelX Ltd.
- This aggregate ownership includes 14,366 shares issuable upon the exercise of pre-funded warrants held by the Reporting Persons and the Partners Managed Account.
- The total beneficial ownership represents 0.6% of NewcelX Ltd.'s outstanding Common Shares, calculated based on 4,558,378 shares outstanding as of October 31, 2025, plus the 14,366 shares from pre-funded warrants.
- The filing states that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 240.14a-11.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding NewcelX Ltd.'s future outlook.
Industry Context
This is a routine disclosure of beneficial ownership by an investment fund, common in the biotechnology sector where specialized funds often take positions in emerging companies. The reported stake of 0.6% is a passive investment and does not suggest any significant strategic shift or activist intent.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, though the percentage is not large enough to suggest control or influence.
Key Dates
| Date | Description |
|---|---|
| 10/31/2025 | Date of event which requires the filing of this statement |
| 11/04/2025 | Date of filing and beneficial ownership calculation |
Keywords
NewcelX Ltd., Biotechnology Value Fund, BVF, Schedule 13G, Beneficial Ownership, Common Shares, Pre-Funded Warrants, H5835A109
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.